Clinical trial
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in…
NCT00252382 · Sunesis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00252382 |
|---|---|
| Title | Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC |
| Official title | Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of the Intravenous Administration of SNS-595 as Second-Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Sunesis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | SNS-595 Injection |
| Enrollment | 31 |
| Start date | Dec 27, 2005 |
| Primary completion | Mar 5, 2007 |
| Completion | Nov 29, 2007 |
| First posted | Nov 11, 2005 |
| Last update posted | Sep 24, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: